PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 185 filers reported holding PROTAGONIST THERAPEUTICS INC in Q1 2024. The put-call ratio across all filers is 2.03 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2024 | $997,159 | +80.0% | 34,468 | +42.7% | 0.02% | +133.3% |
| Q4 2023 | $554,012 | -77.5% | 24,161 | -83.6% | 0.01% | -80.9% |
| Q3 2023 | $2,457,731 | +1426.5% | 147,346 | +625.2% | 0.05% | +571.4% |
| Q2 2022 | $161,000 | -85.5% | 20,317 | -56.6% | 0.01% | -85.7% |
| Q1 2022 | $1,109,000 | – | 46,825 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Johnson & Johnson Innovation - JJDC, Inc. | 2,449,183 | $43,253,000 | 8.50% |
| BVF INC/IL | 2,367,288 | $41,806,000 | 2.58% |
| RTW INVESTMENTS, LP | 3,383,208 | $59,747,000 | 1.68% |
| Novo Holdings A/S | 824,169 | $14,555,000 | 0.94% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 1,013,495 | $17,898,000 | 0.52% |
| Sofinnova Investments, Inc. | 326,064 | $5,758,000 | 0.36% |
| FARALLON CAPITAL MANAGEMENT LLC | 2,500,000 | $44,150,000 | 0.35% |
| Virtus ETF Advisers LLC | 21,639 | $382,000 | 0.18% |
| Baker Brothers Advisors | 1,911,446 | $33,756,000 | 0.15% |
| King Wealth Management Group | 22,000 | $389,000 | 0.11% |